Molecular Templates has created Engineered Toxin Bodies’ (ETBs) libraries that can be rapidly screened on functionality where the target may or may not be known a priori.
ETBs retain the predictable pharmacokinetics, mechanism-of-action, ability to induce internalization, and intracellular self-routing capabilities of the parent scaffold.
These properties allow ETBs to target cell surface or intracellular targets that may be intractable to antibody or small molecule approaches.
Molecular Templates president and CEO Eric Poma said ETBs represent a new class of targeted biologics that possess active intracellular properties that uniquely positions them to address delivery of RNAi drugs in a target directed manner.